Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free CANF Stock Alerts

Can-Fite BioPharma (CANF) Competitors

Can-Fite BioPharma logo
$3.40 0.00 (0.00%)
Closing price 08/28/2026 04:00 PM Eastern
Extended Trading
$3.41 +0.01 (+0.18%)
As of 04:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CANF vs. PBM, CNSP, TRAW, OBSV, and EGRX

Should you buy Can-Fite BioPharma stock or one of its competitors? Can-Fite BioPharma's main competitors and comparable companies include Psyence Biomedical (PBM), CNS Pharmaceuticals (CNSP), Traws Pharma (TRAW), ObsEva (OBSV), and Eagle Pharmaceuticals (EGRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Can-Fite BioPharma compare to Psyence Biomedical?

Can-Fite BioPharma (NYSE:CANF) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Can-Fite BioPharma presently has a consensus target price of $44.00, suggesting a potential upside of 1,194.12%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Psyence Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Psyence Biomedical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Psyence Biomedical N/A N/A N/A

In the previous week, Psyence Biomedical had 2 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Psyence Biomedical and 0 mentions for Can-Fite BioPharma. Psyence Biomedical's average media sentiment score of 1.43 beat Can-Fite BioPharma's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Psyence Biomedical Positive

Can-Fite BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Psyence Biomedical has lower revenue, but higher earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.50-$7.63M-$22.80N/A
Psyence BiomedicalN/AN/A-$6.94M$25.340.17

Summary

Psyence Biomedical beats Can-Fite BioPharma on 8 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to CNS Pharmaceuticals?

Can-Fite BioPharma (NYSE:CANF) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Can-Fite BioPharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market.

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Can-Fite BioPharma has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.50-$7.63M-$22.80N/A
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for Can-Fite BioPharma. CNS Pharmaceuticals' average media sentiment score of 0.93 beat Can-Fite BioPharma's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Can-Fite BioPharma Neutral
CNS Pharmaceuticals Positive

Can-Fite BioPharma presently has a consensus price target of $44.00, suggesting a potential upside of 1,194.12%. CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 262.32%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than CNS Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Can-Fite BioPharma's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
CNS Pharmaceuticals N/A -204.25%-141.87%

Summary

Can-Fite BioPharma beats CNS Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Traws Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Can-Fite BioPharma's return on equity of 0.00% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws PharmaN/A -23,868.92% -165.52%
Can-Fite BioPharma N/A N/A N/A

Traws Pharma currently has a consensus target price of $1.00, indicating a potential upside of 69.52%. Can-Fite BioPharma has a consensus target price of $44.00, indicating a potential upside of 1,194.12%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Traws Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 7.6% of Traws Pharma shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Traws Pharma had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Traws Pharma and 0 mentions for Can-Fite BioPharma. Traws Pharma's average media sentiment score of 1.87 beat Can-Fite BioPharma's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Traws Pharma Very Positive
Can-Fite BioPharma Neutral

Traws Pharma has higher revenue and earnings than Can-Fite BioPharma. Traws Pharma is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$2.79M3.25$9.17M-$1.74N/A
Can-Fite BioPharma$405K5.50-$7.63M-$22.80N/A

Summary

Traws Pharma beats Can-Fite BioPharma on 8 of the 15 factors compared between the two stocks.

How does Can-Fite BioPharma compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
ObsEva Neutral
Can-Fite BioPharma Neutral

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Can-Fite BioPharma has higher revenue and earnings than ObsEva. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ObsEvaN/AN/A-$58.38M-$0.92N/A
Can-Fite BioPharma$405K5.50-$7.63M-$22.80N/A

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity.

Company Net Margins Return on Equity Return on Assets
ObsEvaN/A -416.36% -92.01%
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 1,194.12%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than ObsEva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ObsEva
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Can-Fite BioPharma beats ObsEva on 9 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$257.55M0.05$35.64M$1.180.78
Can-Fite BioPharma$405K5.50-$7.63M-$22.80N/A

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Eagle PharmaceuticalsN/A N/A N/A
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has a consensus target price of $44.00, indicating a potential upside of 1,194.12%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for Can-Fite BioPharma. Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
Eagle Pharmaceuticals Neutral
Can-Fite BioPharma Neutral

Summary

Eagle Pharmaceuticals beats Can-Fite BioPharma on 7 of the 12 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CANF vs. The Competition

Export
MetricCan-Fite BioPharmaPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$2.23M$12.11B$7.18B$24.12B
Dividend YieldN/A2.62%2.54%3.72%
P/E Ratio-1.90787.65273.1730.01
Price / Sales5.50759.94638.2123.53
Price / CashN/A15.3228.7419.75
Price / Book1.9310.4911.084.84
Net Income-$7.63M$2.83B$3.48B$1.07B
7 Day Performance1.49%0.58%0.38%-0.41%
1 Month Performance7.94%5.69%7.89%2.04%
1 Year Performance-73.08%6.19%24.71%13.37%

Can-Fite BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CANF
Can-Fite BioPharma
N/A$3.40
flat		$44.00
+1,194.1%		-73.1%$2.23M$405KN/A8
PBM
Psyence Biomedical
1.908 of 5 stars		$3.97
-11.2%		N/A-76.0%$9.09MN/A0.16N/A
CNSP
CNS Pharmaceuticals
2.2463 of 5 stars		$6.08
+3.8%		$20.00
+228.9%		-11.3%$8.88MN/AN/A5
TRAW
Traws Pharma
2.5276 of 5 stars		$0.55
+2.4%		$1.00
+80.8%		-57.9%$8.38M$2.79MN/A17
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:CANF) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel